Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients: A systematic review and meta‐analysis

Published:2022-05-20 Issue: Volume: Page:
ISSN:1354-523X
Container-title:Oral Diseases
language:en
Short-container-title:Oral Diseases

Author:

Kiss Fruzsina¹²³⁴,Pohóczky Krisztina²³⁵^ORCID,Görbe Anikó⁴,Dembrovszky Fanni³⁴,Kiss Szabolcs³⁴⁶,Hegyi Péter³⁴,Szakó Lajos³⁴,Tóth Lilla²,Ezer Éva Somogyiné¹,Szalai Eszter⁷,Helyes Zsuzsanna²³

Affiliation:

1. Somogy County Kaposi Mór Teaching Hospital Kaposvár Hungary

2. Department of Pharmacology and Pharmacotherapy Medical School University of Pécs Pécs Hungary

3. János Szentágothai Research Centre & Centre for Neuroscience University of Pécs Pécs Hungary

4. Institute for Translational Medicine Medical School University of Pécs Pécs Hungary

5. Department of Pharmacology Faculty of Pharmacy University of Pécs Pécs Hungary

6. Doctoral School of Clinical Medicine University of Szeged Szeged Hungary

7. Department of Ophthalmology University of Pécs Pécs Hungary

Funder

Hungarian Academy of Sciences

Publisher

Wiley

Subject

General Dentistry,Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/odi.14228

Reference66 articles.

1. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer

2. Phase III Randomized, Placebo-Controlled Trial of Docetaxel With or Without Gefitinib in Recurrent or Metastatic Head and Neck Cancer: An Eastern Cooperative Oncology Group Trial

3. Head and neck cancer

4. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy

5. Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach;Frontiers in Oral Health;2024-08-02

2. Evaluation of Five-year Overall Survival Rates Among 18,331 Head and Neck Cancer Patients Exposed to Different Targeted Therapies Through Real-world Data in a Case-controlled Study;Anticancer Research;2024-02-29

3. MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers;International Journal of Molecular Sciences;2023-02-01

4. In vitro study of the antimitotic power and in vivo acute toxicity of aqueous and organic extracts of the aerial part of Haloxylon scoparium Pomel. and evaluation of the correlation between the chemical profile and their biological activities;Plant Science Today;2022-12-22

5. Anti-EGFR monoclonal antibody Cetuximab displays potential anti-cancer activities in feline oral squamous cell carcinoma cell lines;Frontiers in Veterinary Science;2022-11-17